Your browser doesn't support javascript.
loading
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.
Harding, James J; Fan, Jia; Oh, Do-Youn; Choi, Hye Jin; Kim, Jin Won; Chang, Heung-Moon; Bao, Lequn; Sun, Hui-Chuan; Macarulla, Teresa; Xie, Feng; Metges, Jean-Phillippe; Ying, Jie'er; Bridgewater, John; Lee, Myung-Ah; Tejani, Mohamedtaki A; Chen, Emerson Y; Kim, Dong Uk; Wasan, Harpreet; Ducreux, Michel; Bao, Yuanyuan; Boyken, Lisa; Ma, Jiafang; Garfin, Phillip; Pant, Shubham.
Affiliation
  • Harding JJ; Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: hardinj1@mskcc.org.
  • Fan J; Zhongshan Hospital of Fudan University, Shanghai, China.
  • Oh DY; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, South Korea.
  • Choi HJ; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
  • Kim JW; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.
  • Chang HM; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Bao L; Hubei Cancer Hospital, Wuhan, Hubei, China.
  • Sun HC; Zhongshan Hospital of Fudan University, Shanghai, China.
  • Macarulla T; Vall d'Hebrón University Hospital, Vall d'Hebrón Institute of Oncology (VHIO), Barcelona, Spain.
  • Xie F; The Third Affiliated Hospital of the Chinese PLA Naval Military Medical University, Shanghai, China.
  • Metges JP; CHRU de Brest - Hopital Morvan, ARPEGO Network, Brest, France.
  • Ying J; Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
  • Bridgewater J; University College London Cancer Institute, London, UK.
  • Lee MA; The Catholic University of Korea, Seoul St Mary's Hospital, Seoul, South Korea.
  • Tejani MA; AdventHealth, Altamonte Springs, FL, USA.
  • Chen EY; Oregon Health & Science University, Portland, OR, USA.
  • Kim DU; Biomedical Research Institute, Pusan National University Hospital, Busan, South Korea.
  • Wasan H; Hammersmith Hospital, Imperial College London, London, UK.
  • Ducreux M; Université Paris-Saclay, Gustave Roussy, Villejuif, France.
  • Bao Y; BeiGene, Beijing, China.
  • Boyken L; Zymeworks, Vancouver, BC, Canada.
  • Ma J; BeiGene, Beijing, China.
  • Garfin P; Zymeworks, Vancouver, BC, Canada.
  • Pant S; MD Anderson Cancer Center, Houston, TX, USA.
Lancet Oncol ; 24(7): 772-782, 2023 07.
Article in En | MEDLINE | ID: mdl-37276871
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bile Duct Neoplasms / Biliary Tract Neoplasms / Antineoplastic Agents Type of study: Clinical_trials Limits: Female / Humans / Male / Middle aged Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2023 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bile Duct Neoplasms / Biliary Tract Neoplasms / Antineoplastic Agents Type of study: Clinical_trials Limits: Female / Humans / Male / Middle aged Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2023 Document type: Article Country of publication: